Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | CPT1A | P50416 | 1/20 | 0.35 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zinc Ion SCHEMBL2580359 | 0.99 | EPHX2 (0.42) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| SCHEMBL3276927 | 0.97 | EPHX2 (0.46) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| Zinc Ion SCHEMBL2577660 | 0.89 | KMT2A (0.33) | EPHX2NOD1KMT2A | |
| SCHEMBL4425978 | 0.88 | EPHX2 (0.37) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2585203 | 0.86 | NMT1 (0.34) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2577508 | 0.84 | FOLH1 (0.36) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2580310 | 0.84 | SLC6A5 (0.43) | NOD1 | |
| Zinc Ion SCHEMBL2574083 | 0.83 | NOD1 (0.44) | EPHX2CPT2CPT1ACPT1BNOD1 | |
| Zinc Ion SCHEMBL2574899 | 0.82 | FNTA (0.46) | EPHX2NOD1KMT2A | |
| Zinc Ion SCHEMBL2582837 | 0.79 | FAAH (0.40) | CPT2CPT1ACPT1BNOD1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | SENJU PHARMACEUTICAL CO. LTD. (JP) | 2010-06-17 | — | — | US | claimed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | claimed |
| EP-1371640-B1 | NOVEL A-LIPOIC ACID DERIVATIVE AND USE THEREOF | SENJU PHARMA CO (JP) | 2009-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152288-A1 | NOVEL a-LIPOIC ACID DERIVATIVES AND APPLICATIONS THEREOF | TYR, SERPINB1, LPO | EPHX2 1159/4885CPT2 2989/4885CPT1A 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.